{
    "clinical_study": {
        "@rank": "104201", 
        "acronym": "JUNGLO", 
        "arm_group": [
            {
                "arm_group_label": "Damira/Celia peptide hydrolyzed casein", 
                "arm_group_type": "Experimental", 
                "description": "Extensively Hydrolyzed (EH)casein infant formula"
            }, 
            {
                "arm_group_label": "Picot riz/Celia rice/Sanutri arroz", 
                "arm_group_type": "Experimental", 
                "description": "Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this double blinded randomized study is to assess the tolerance of two\n      extensively protein hydrolyzed infant formulas, one based on rice protein and the other one\n      on casein, at introduction, and after 3 months of consumption, and their efficacy on growth\n      and on the reduction of allergy symptoms through a 3 months consumption period."
        }, 
        "brief_title": "Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cow Milk Protein Sensitivity", 
            "Tolerance", 
            "Growth Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Failure to Thrive", 
                "Milk Hypersensitivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Full term healthy newborns (37-42 Weeks gestation)\n\n          -  Weight at birth \u2265 2500 g\n\n          -  Aged between birth to 9 months\n\n          -  Symptoms of allergy (Skin or digetive)\n\n          -  Suspicion of cow milk protein allergy\n\n          -  Infants whose parents/caregivers/legal guardians have the ability to understand and\n             comply with the requirements of the study\n\n          -  Infants whose parents/caregivers/legal guardians gave their written informed consent\n             to the infant's participation in the study\n\n        Exclusion Criteria:\n\n          -  Children who have returned to breastfeeding\n\n          -  Presence of any condition, that, in the opinion of the investigator is a\n             contra-indication to the particpation of the infant in the study\n\n          -  In the past 15 days, treatment or medication likely to :\n\n               -  induce confusion in the allergy tets (ex. : Skin Prick Test) and / or\n\n               -  mask the symptoms of an allergic reaction (Anti-allergy medications ;\n                  anti-histaminic, anti-leucotrienes, corticosteroids, \u2026)\n\n          -  Newbonrs presenting a chronic or a genetic malformation, or a chromosomal or other\n             disease, that in the opinion of the investigator could mask the study results\n\n          -  Children who show signs of malnutrition, or prolonged diarrhea\n\n          -  Children whose parents show no willingness to comply with study requirements\n\n          -  Consumption of soya protein based, hydrolyzed protein or elemental (amino acid)\n             formula for more than 21 days before inclusion, unless the skin prick test to cow's\n             milk protein is positive, and the IgE level indicates the existence of IgE mediated\n             allergy to cow's milk protein."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "9 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909661", 
            "org_study_id": "LRD - 2013 - JUNGLO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Damira/Celia peptide hydrolyzed casein", 
                "intervention_name": "Damira/Celia peptide hydrolyzed casein", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Picot riz/Celia rice/Sanutri arroz", 
                "intervention_name": "Picot riz/Celia rice/Sanutri arroz", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Caseins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "allergy", 
            "Cow's milk protein", 
            "Tolerance", 
            "Efficacy", 
            "Infants' growth"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "contact": {
                "email": "Juristo.FonollaJoya@biosearchlife.com", 
                "last_name": "Juristo Fonoll\u00e1 Joya", 
                "phone": "+34 958240288 / +34 6188063"
            }, 
            "contact_backup": {
                "email": "MariaPaz.DiazRopero@biosearchlife.com", 
                "last_name": "Maria Paz Diaz Ropero", 
                "phone": "+34 958 230 469"
            }, 
            "facility": {
                "address": {
                    "city": "Granada", 
                    "country": "Spain", 
                    "zip": "18004"
                }, 
                "name": "Biosearch S.A."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tolerancia a 2 f\u00f3rmulas de Leche Infantil Altamente Hidrolizadas en Base a prote\u00ednas de Arroz y a case\u00edna en ni\u00f1os Con Alergia a Las prote\u00ednas de Leche de Vaca", 
        "other_outcome": {
            "description": "Volume of infant formula consumed by the infants in 3 months", 
            "measure": "Volume of infant formula consumed by the infants", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "jacqueline.brasy@lactalis.fr", 
            "last_name": "Jacqueline Brasy", 
            "phone": "+33299475084"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tolerance is absence of clinical signs.", 
            "measure": "Proportion of infants who tolerate either the rice hydrolyzed protein infant formula or a hydrolyzed casein infant formula after 24h consumption.", 
            "safety_issue": "Yes", 
            "time_frame": "24h"
        }, 
        "removed_countries": {
            "country": "France"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909661"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluate during 3 months of consumption the effectiveness of the formulas, in terms of :\ninfant growth, through anthropometric measures (body weight, length and head circumference)\nallergy symptoms, through the improvement of the allergy symptoms.", 
            "measure": "Effectivness of the hydrolyzed protein formulas in terms of growth and allergy symptoms improvement.", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Lactalis", 
        "sponsors": {
            "collaborator": {
                "agency": "Biosearch S.A.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Lactalis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}